Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 85

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Visit website
Immunotherapy Web Featured Images 81

Use of daratumumab for transplant-ineligible myeloma

During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

Visit website
Immunotherapy Web Featured Images 84

Scientists create ON-OFF switches to control CAR T cell activity

Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.

Visit website
Patient Power

Patient Resource: Latest News on CAR T-Cell Therapy for Multiple Myeloma

  Jan 07 2021 Tagged CAR-T, MM

How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?

Visit website
Immunotherapy Web Featured Images 86

Interim results from ZUMA-12: Axi-cel as frontline treatment for high-risk LBCL

Patients with high-risk large B-cell lymphoma (LBCL) are mainly treated with rituximab-based chemoimmunotherapies that do not provide sufficient efficacy, as approximately 50% of these patients will not achieve long-term disease remission.

Visit website
Immunotherapy Web Featured Images 77

T-cell engaging antibodies for hematological diseases from approved therapies to...

Are bispecific antibodies less effective (and less toxic) than CAR-T cells? This educational video from the EHA25 congress shows us that the race between CAR-T therapy and bispecific Abs for hematological diseases is still ongoing!

Visit website

Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review

The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.

Visit website

Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs

  Jan 04 2021 Tagged CAR-T, LBCL

During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.

Visit website

Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients.

Visit website

DARAZADEX: a Phase II trial of daratumumab plus azacitidine and dexamethasone in...

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, shares the details of an ongoing Phase II trial (NCT04407442) of daratumumab, an anti-CD38 monoclonal antibody, in combination with azacitidine and dexamethasone in relapsed/refractory (R/R) multiple myeloma patients.

Visit website